Affimed N.V.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Shawn M. Leland Pharm.D., R.Ph.
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Technologiepark Heidelberg Germany 69120
- IPO Date
- Sep 12, 2014
- CIK
- 0001608390
- Website
- affimed.com
- Similar Companies
- Business
- Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Company News
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Affimed Appoints New CEO, Shares Fall on Leadership Change
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed Announces Annual General Meeting of Shareholders
7 Penny Biotech Stocks to Triple Your Investment
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade